Marginal increase of sunitinib exposure by grapefruit juice

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 3, 2011, Pages 695-703

  Van Erp, Nielka P ^a   Baker, Sharyn D ^b   Zandvliet, Anthe S ^c   Ploeger, Bart A ^d   Den Hollander, Margaret ^a   Chen, Zhaoyuan ^b   Den Hartigh, Jan ^a   König Quartel, Jacqueline M C ^a   Guchelaar, Henk Jan ^a   Gelderblom, Hans ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c LAPandP Consultants BV ^*

^d LAPandP Consultants BV   (Netherlands)

Author keywords

CYP3A4 inhibition; Grapefruit juice; Pharmacokinetics; Sunitinib

Indexed keywords

CYTOCHROME P450 3A4; MIDAZOLAM; SUNITINIB; ANTINEOPLASTIC AGENT; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DIETARY INTAKE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; ENZYME ACTIVITY; FEMALE; FOOD DRUG INTERACTION; GASTROINTESTINAL STROMAL TUMOR; GRAPEFRUIT JUICE; HUMAN; KIDNEY CARCINOMA; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; BEVERAGE; BIOAVAILABILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; DRUG LABELING; GRAPEFRUIT; METABOLISM; MIDDLE AGED; NEOPLASM; PATHOLOGY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BEVERAGES; BIOLOGICAL AVAILABILITY; CITRUS PARADISI; CYTOCHROME P-450 CYP3A; DRUG LABELING; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; INDOLES; MALE; MIDAZOLAM; MIDDLE AGED; NEOPLASMS; PYRROLES;

EID: 79953312829     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1367-0     Document Type: Article

References (45)

1. RJ Motzer TE Hutson P Tomczak MD Michaelson RM Bukowski O Rixe S Oudard S Negrier C Szczylik ST Kim I Chen PW Bycott CM Baum RA Figlin 2007 Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 115 124 1:CAS:528:DC%2BD2sXksVGqsw%3D%3D 10.1056/NEJMoa065044 17215529 (Pubitemid 46089672)
2. GD Demetri AT van Oosterom CR Garrett ME Blackstein MH Shah J Verweij G McArthur IR Judson MC Heinrich JA Morgan J Desai CD Fletcher S George CL Bello X Huang CM Baum PG Casali 2006 Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 368 1329 1338 1:CAS:528:DC%2BD28XhtVOrtL%2FL 10.1016/S0140-6736(06)69446-4 17046465 (Pubitemid 44528723)
3. VL Goodman EP Rock R Dagher RP Ramchandani S Abraham JV Gobburu BP Booth SL Verbois DE Morse CY Liang N Chidambaram JX Jiang S Tang K Mahjoob R Justice R Pazdur 2007 Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma Clin Cancer Res 13 1367 1373 1:CAS:528:DC%2BD2sXitlSjsbc%3D 10.1158/1078-0432.CCR-06-2328 17332278 (Pubitemid 46450424)
4. S Faivre C Delbaldo K Vera C Robert S Lozahic N Lassau C Bello S Deprimo N Brega G Massimini JP Armand P Scigalla E Raymond 2006 Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer J Clin Oncol 24 25 35 1:CAS:528: DC%2BD28Xot1ChtQ%3D%3D 10.1200/JCO.2005.02.2194 16314617 (Pubitemid 46630490)
5. CL Bello L Sherman J Zhou L Verkh J Smeraglia J Mount KJ Klamerus 2006 Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects Anticancer Drug 17 353 358 1:CAS:528:DC%2BD28XitVGnur8%3D 10.1097/00001813-200603000-00015
6. BE Houk CL Bello D Kang M Amantea 2009 A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients Clin Cancer Res 15 2497 2506 1:CAS:528:DC%2BD1MXjvVWksLg%3D 10.1158/1078-0432.CCR-08-1893 19258444
7. VR Adams M Leggas 2007 Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors Clin Ther 29 1338 1353 1:CAS:528:DC%2BD2sXhtVemurjM 10.1016/j.clinthera.2007.07.022 17825686 (Pubitemid 47348120)
8. Pfizer (2006) Drug label Sutent approved 01/26/2006. http://www. accessdata.fda.gov/scripts/cder/drugsatfda/. Accessed on 02/18/2009. 2006
9. S Shukla RW Robey SE Bates SV Ambudkar 2009 Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2 Drug Metab Dispos 37 359 365 1:CAS:528:DC%2BD1MXhs1Krsbo%3D 10.1124/dmd.108.024612 18971320
10. Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, Sparreboom A, and Baker SD (2009) Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin.Cancer Res (In press)
11. DG Bailey J Malcolm O Arnold JD Spence 1998 Grapefruit juice-drug interactions Br J Clin Pharmacol 46 101 110 1:CAS:528:DyaK1cXlsFCitrY%3D 10.1046/j.1365-2125.1998.00764.x 9723817 (Pubitemid 28342779)
12. P Schmiedlin-Ren DJ Edwards ME Fitzsimmons K He KS Lown PM Woster A Rahman KE Thummel JM Fisher PF Hollenberg PB Watkins 1997 Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins Drug Metab Dispos 25 1228 1233 1:CAS:528:DyaK2sXntlOku7g%3D 9351897 (Pubitemid 27490665)
13. EJ Wang CN Casciano RP Clement WW Johnson 2001 Inhibition of P-glycoprotein transport function by grapefruit juice psoralen Pharm Res 18 432 438 1:CAS:528:DC%2BD3MXkvFCgu7Y%3D 10.1023/A:1011089924099 11451028 (Pubitemid 32592573)
14. MF Paine AB Criss PB Watkins 2004 Two major grapefruit juice components differ in intestinal CYP3A4 inhibition kinetic and binding properties Drug Metab Dispos 32 1146 1153 1:CAS:528:DC%2BD2cXot12ltbk%3D 10.1124/dmd.104.000547 15269184 (Pubitemid 39287589)
15. TC Goosen D Cillie DG Bailey C Yu K He PF Hollenberg PM Woster L Cohen JA Williams M Rheeders HP Dijkstra 2004 Bergamottin contribution to the grapefruit juice-felodipine interaction and disposition in humans Clin Pharmacol Ther 76 607 617 1:CAS:528:DC%2BD2cXhtVKlt7vP 10.1016/j.clpt.2004.08.019 15592332 (Pubitemid 39601550)
16. J Rashid C McKinstry AG Renwick M Dirnhuber DG Waller CF George 1993 Quercetin, an in vitro inhibitor of CYP3A, does not contribute to the interaction between nifedipine and grapefruit juice Br J Clin Pharmacol 36 460 463 1:CAS:528:DyaK2cXpsVyjtw%3D%3D 12959295 (Pubitemid 23344157)
17. MF Paine WW Widmer HL Hart SN Pusek KL Beavers AB Criss SS Brown BF Thomas PB Watkins 2006 A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction Am J Clin Nutr 83 1097 1105 1:CAS:528:DC%2BD28XkvFOrsbs%3D 16685052 (Pubitemid 44713110)
18. M Saito M Hirata-Koizumi M Matsumoto T Urano R Hasegawa 2005 Undesirable effects of citrus juice on the pharmacokinetics of drugs: focus on recent studies Drug Saf 28 677 694 1:CAS:528:DC%2BD2MXhtVWjsLnN 10.2165/00002018- 200528080-00003 16048354 (Pubitemid 41132455)
19. MF Paine WW Widmer SN Pusek KL Beavers AB Criss J Snyder PB Watkins 2008 Further characterization of a furanocoumarin-free grapefruit juice on drug disposition: studies with cyclosporine Am J Clin Nutr 87 863 871 1:CAS:528:DC%2BD1cXkvFeht7Y%3D 18400708 (Pubitemid 351549230)
20. SU Mertens-Talcott I Zadezensky WV De Castro H Derendorf V Butterweck 2006 Grapefruit-drug interactions: can interactions with drugs be avoided? J Clin Pharmacol 46 1390 1416 1:CAS:528:DC%2BD28XhtlajsbvJ 10.1177/ 0091270006294277 17101740 (Pubitemid 44704201)
21. S Reif MC Nicolson D Bisset M Reid C Kloft U Jaehde HL McLeod 2002 Effect of grapefruit juice intake on etoposide bioavailability Eur J Clin Pharmacol 58 491 494 1:CAS:528:DC%2BD38XnvFOhtb4%3D 10.1007/s00228-002-0495-9 12389073 (Pubitemid 35244924)
22. OQ Yin N Gallagher A Li W Zhou R Harrell H Schran 2010 Effect of grapefruit juice on the pharmacokinetics of nilotinib in healthy participants J Clin Pharmacol 50 188 194 1:CAS:528:DC%2BC3cXks1Sksbg%3D 10.1177/ 0091270009336137 19948946
23. WV De Castro S Mertens-Talcott A Rubner V Butterweck H Derendorf 2006 Variation of flavonoids and furanocoumarins in grapefruit juices: a potential source of variability in grapefruit juice-drug interaction studies J Agric Food Chem 54 249 255 10.1021/jf0516944 16390207 (Pubitemid 43119947)
24. P Minkin M Zhao Z Chen J Ouwerkerk H Gelderblom SD Baker 2008 Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry J Chromatogr B Analyt Technol Biomed Life Sci 874 84 88 1:CAS:528:DC%2BD1cXht1egtbzO 10.1016/j.jchromb.2008.09.007 18823825
25. Beal SL, Boeckman AJ, Sheiner LB (1988) NONMEM user's guides. University of California at San Francisco, San Francisco CA
26. U Wahlby EN Jonsson MO Karlsson 2001 Assessment of actual significance levels for covariate effects in NONMEM J Pharmacokinet Pharmacodyn 28 231 252 1:STN:280:DC%2BD38%2FitlOktA%3D%3D 10.1023/A:1011527125570 11468939 (Pubitemid 32643366)
27. DJ Greenblatt LL von Moltke JS Harmatz G Chen JL Weemhoff C Jen CJ Kelley BW LeDuc MA Zinny 2003 Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice Clin Pharmacol Ther 74 121 129 1:CAS:528:DC%2BD3sXlvVCrt70%3D 10.1016/S0009-9236(03)00118-8 12891222 (Pubitemid 36951809)
28. MO Karlsson RM Savic 2007 Diagnosing model diagnostics Clin Pharmacol Ther 82 17 20 1:STN:280:DC%2BD2szlvVakug%3D%3D 10.1038/sj.clpt.6100241 17571070 (Pubitemid 46944205)
29. JJ Lilja KT Kivisto PJ Neuvonen 2000 Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin Clin Pharmacol Ther 68 384 390 1:CAS:528:DC%2BD3cXot1Wjtr4%3D 10.1067/mcp.2000.110216 11061578
30. KE Culm-Merdek LL von Moltke L Gan KA Horan R Reynolds JS Harmatz MH Court DJ Greenblatt 2006 Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir Clin Pharmacol Ther 79 243 254 1:CAS:528:DC%2BD28XitVKhurg%3D 10.1016/j.clpt.2005.11.009 16513448
31. HH Kupferschmidt HR Ha WH Ziegler PJ Meier S Krahenbuhl 1995 Interaction between grapefruit juice and midazolam in humans Clin Pharmacol Ther 58 20 28 1:CAS:528:DyaK2MXntlKkt70%3D 10.1016/0009-9236(95)90068-3 7628179
32. H Satoh F Yamashita M Tsujimoto H Murakami N Koyabu H Ohtani Y Sawada 2005 Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B Drug Metab Dispos 33 518 523 1:CAS:528:DC%2BD2MXjtFCjsrw%3D 10.1124/dmd.104.002337 15640378 (Pubitemid 40393194)
33. GK Dresser DG Bailey BF Leake UI Schwarz PA Dawson DJ Freeman RB Kim 2002 Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine Clin Pharmacol Ther 71 11 20 1:CAS:528:DC%2BD38XitFOgs7c%3D 10.1067/mcp.2002.121152 11823753 (Pubitemid 34124034)
34. H Glaeser DG Bailey GK Dresser JC Gregor UI Schwarz JS McGrath E Jolicoeur W Lee BF Leake RG Tirona RB Kim 2007 Intestinal drug transporter expression and the impact of grapefruit juice in humans Clin Pharmacol Ther 81 362 370 1:CAS:528:DC%2BD2sXktl2ltbY%3D 10.1038/sj.clpt.6100056 17215845 (Pubitemid 46364477)
35. M Hermann A Asberg JL Reubsaet S Sather KJ Berg H Christensen 2002 Intake of grapefruit juice alters the metabolic pattern of cyclosporin A in renal transplant recipients Int J Clin Pharmacol Ther 40 451 456 1:CAS:528: DC%2BD38XotlGkur8%3D 12395977
36. DG Bailey GK Dresser BF Leake RB Kim 2007 Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice Clin Pharmacol Ther 81 495 502 1:CAS:528:DC%2BD2sXkvFymu74%3D 10.1038/sj.clpt.6100104 17301733 (Pubitemid 46452308)
37. VA Eagling L Profit DJ Back 1999 Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components Br J Clin Pharmacol 48 543 552 1:CAS:528:DyaK1MXmvFaksr8%3D 10.1046/j.1365-2125.1999.00052.x 10583025 (Pubitemid 29454235)
38. RM Franke SD Baker RH Mathijssen EG Schuetz A Sparreboom 2008 Influence of solute carriers on the pharmacokinetics of CYP3A4 probes Clin Pharmacol Ther 84 704 709 1:CAS:528:DC%2BD1cXhtlOjtr%2FF 10.1038/clpt.2008.94 18509328
39. U Fuhr A Jetter J Kirchheiner 2007 Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach Clin Pharmacol Ther 81 270 283 1:CAS:528:DC%2BD2sXisFyrtbc%3D 10.1038/sj.clpt.6100050 17259951 (Pubitemid 46174825)
40. RB Kim C Wandel B Leake M Cvetkovic MF Fromm PJ Dempsey MM Roden F Belas AK Chaudhary DM Roden AJ Wood GR Wilkinson 1999 Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein Pharm Res 16 408 414 1:CAS:528:DyaK1MXisFWntLo%3D 10.1023/A:1018877803319 10213372 (Pubitemid 29162099)
41. D Kurnik AJ Wood GR Wilkinson 2006 The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity Clin Pharmacol Ther 80 228 234 1:CAS:528:DC%2BD28XptFCgu7o%3D 10.1016/j.clpt.2006.06. 002 16952489 (Pubitemid 44301092)
42. D Farkas LE Oleson Y Zhao JS Harmatz MA Zinny MH Court DJ Greenblatt 2007 Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: comparison with grapefruit juice J Clin Pharmacol 47 286 294 1:CAS:528:DC%2BD2sXjsVyjtr8%3D 10.1177/0091270006298359 17322140 (Pubitemid 46294718)
43. ML Veronese LP Gillen JP Burke EP Dorval WW Hauck E Pequignot SA Waldman HE Greenberg 2003 Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice J Clin Pharmacol 43 831 839 1:CAS:528: DC%2BD3sXmsFyqtb8%3D 10.1177/0091270003256059 12953340 (Pubitemid 36886103)
44. SC Mueller J Majcher-Peszynska RG Mundkowski B Uehleke S Klammt H Sievers R Lehnfeld B Frank K Thurow G Kundt B Drewelow 2009 No clinically relevant CYP3A induction after St. John's wort with low hyperforin content in healthy volunteers Eur J Clin Pharmacol 65 81 87 1:CAS:528:DC%2BD1cXhsFSrur%2FL 10.1007/s00228-008-0554-y 18762932
45. NP van Erp H Gelderblom MO Karlsson J Li M Zhao J Ouwerkerk JW Nortier HJ Guchelaar SD Baker A Sparreboom 2007 Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib Clin Cancer Res 13 7394 7400 10.1158/1078-0432.CCR-07-0346 18094422